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ABSTRACT
Introduction: Apathy, agitated behaviours, loneliness
and depression are common consequences of
dementia. This trial aims to evaluate the effect of a
robotic animal on behavioural and psychological
symptoms of dementia in people with dementia living
in long-term aged care.
Methods and analysis: A cluster-randomised
controlled trial with three treatment groups: PARO
(robotic animal), Plush-Toy (non-robotic PARO) or
Usual Care (Control). The nursing home sites are
Australian Government approved and accredited
facilities of 60 or more beds. The sites are located in
South-East Queensland, Australia. A sample of 380
adults with a diagnosis of dementia, aged 60 years or
older living in one of the participating facilities will be
recruited. The intervention consists of three individual
15 min non-facilitated sessions with PARO or Plush-
Toy per week, for a period of 10 weeks. The primary
outcomes of interest are improvement in agitation,
mood states and engagement. Secondary outcomes
include sleep duration, step count, change in
psychotropic medication use, change in treatment
costs, and staff and family perceptions of PARO or
Plush-Toy. Video data will be analysed using Noldus
XT Pocket Observer; descriptive statistics will be used
for participants’ demographics and outcome measures;
cluster and individual level analyses to test all
hypotheses and Generalised Linear Models for cluster
level and Generalised Estimation Equations and/or
Multi-level Modeling for individual level data.
Ethics and dissemination: The study participants or
their proxy will provide written informed consent. The
Griffith University Human Research Ethics Committee
has approved the study (NRS/03/14/HREC). The results
of the study will provide evidence of the efficacy of a
robotic animal as a psychosocial treatment for the
behavioural and psychological symptoms of dementia.
Findings will be presented at local and international
conference meetings and published in peer-reviewed
journals.
Trial registration number: Australian and New
Zealand Clinical Trials Registry number
ACTRN12614000508673 date registered 13/05/2014.
INTRODUCTION
Background
Approximately 35.6 million people globally
and 330 000 Australians1 have dementia.
With the ageing of the population, this
number is expected to double every
20 years.2 Dementia is one of the major
reasons for admission into long-term aged
care. People with dementia may present
with agitated behaviours that cause stress for
the person him/herself, those who care for
them, and other residents in care facilities.
Apathy, loneliness and depression also com-
monly occur in people with dementia and
can make it challenging for care staff to
engage them in meaningful activities, which
in turn places them at high risk for further
Strengths and limitations of this study
▪ The study proposes the assessment of a novel
technology that people with dementia can inter-
act with.
▪ The strengths of the study include its relatively
large sample size, three treatment groups, long-
term sustainability follow-up, video and physio-
logical data and comparative cost analysis.
▪ Limitations include the intervention being con-
ducted only during the afternoon rather than at
the onset of agitation, and no comparison
between a live animal and robot animal.
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cognitive and functional decline.3 Over 50% of all resi-
dents with dementia in Australia are reported to have
behaviours such as physical aggression, agitation, vocal
disruption and chronic mood disturbance.1 Many of
the behavioural and psychological symptoms of demen-
tia, such as agitation, can lead to staff stress and
burnout,4 and can also result in negative staff attitudes
and reduced empathy.5 Consequently, feelings of frus-
tration and agitation are heightened, which may lead
to the additional regular use of antipsychotic medica-
tion.1 Serious adverse drug effects include increase risk
of stroke, sedation, confusion, falls and mortality in
addition to the high cost of pharmaceutical treatment
and overuse.6 This project aims to assess the impact of
a robotic animal called PARO on agitation, mood
states, and engagement, sleep duration, step count,
change in psychotropic medication use, change in
treatment costs and staff and family perceptions of
PARO or Plush-Toy.
Rationale for the proposed trial
Robotic pets, also called emotional or therapeutic
robots, have recently been introduced as companions
for people with cognitive impairment or/and physical
problems.7–9 The advantages of robotic pets have been
listed as: its highly imitative, life-like behaviour; the mod-
elling of emotional states usually experienced by
humans; and the provision of alternative models of com-
munication (eg, tactile-kinesthetic, visual sensory, emo-
tional and social). In addition an interaction can occur
between a resident and robotic animal without the need
for a carer to be present (ie, robotic pets can fill those
inevitable gaps in the day when the resident is alone
because the carer is otherwise occupied). Descriptive
studies have reported improvements in relationships and
loneliness, relaxation and motivation, and socialisation
in older people who have interacted with pet-type
robots.7–9 Previous research in a Japanese aged care
facility found that PARO, a harp seal robot, increased
residents’ social interaction and decreased stress.10
These international studies, however, are limited by
serious methodological problems including small
sample sizes (or single-case studies), no control groups,
limited outcome measures, and studies including both
people with and without dementia. It remains unclear
whether therapeutic robots such as PARO have more
benefit compared with non-robotic interventions or
usual care for dementia related problems such as agita-
tion, reduced mood and lack of engagement. The
current study seeks to extend the existing evidence
about robotic animal therapy. It will build on the find-
ings of our pilot study11 and provide evidence to deter-
mine whether PARO is, indeed, a short-term, low-risk,
non-pharmacological intervention that produces tan-
gible, positive psychological outcomes for people with
dementia.
AIMS
This cluster-randomised controlled trial (C-RCT), in
which long-term care (LTC) facilities will be randomised
to one of three treatment groups (PARO, Plush Toy or
Usual Care (UC)), aims to:
1. Compare UC with an innovative interactive thera-
peutic robot (PARO) and a look-alike Plush Toy (PT
—A PARO with the artificial intelligence and robotic
aspects disabled) in reducing agitation, improving
mood states and engagement; as well as improving
physical activity and sleep duration.
2. Evaluate the acceptability of PARO and Plush Toy for
staff and family.
3. Conduct a comparative cost analysis of PARO and
Plush-Toy with UC as non-pharmacological treatment
alternatives to manage and reduce agitation, and
improve mood states and engagement in people with
dementia.
METHODS
Study setting
This study will be a multisite trial in 35 Australian
Government approved and accredited LTC facilities of
60 or more beds in South East Queensland, Australia,
within a 100 km radius of the Brisbane central business
district. All participants will be living in one of the par-
ticipating facilities.
Trial design
The trial is a C-RCT. A C-RCT eliminates the potential
for contamination in a simple RCT where residents in
the same facility are allocated to different groups and
participants in the control group might be inadvertently
exposed to the intervention due to the nature and
layout of care facilities. Because PARO moves and makes
noise, a C-RCT will also help to ensure blinding (for par-
ticipants, family and staff members) is not compromised.
Eligibility criteria
We will recruit 380 residents, aged 60 years or older
from the 35 participating facilities with a range of demo-
graphic profiles, a documented diagnosis of dementia
(any type) or severity; and a Rowland Universal
Dementia Assessment Scale (RUDAS)12 score of 22 or
less (to accommodate Culturally and Linguistically
Diverse People).
We will exclude residents who are in respite care or
have: a dual diagnosis of a serious or persistent mental
illness (eg, schizophrenia); a terminal illness; or experi-
encing unremitting pain or distressing physical symp-
toms. Simultaneous use of PARO or PT will not be
permitted during the trial.
Study intervention
PARO
Participants at sites allocated to the PARO treatment
group will receive three individual non-facilitated 15 min
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PARO sessions per week (Mon, Wed, Fri), between the
hours of 1300–1700, for a period of 10 weeks. PARO,
developed by Dr Shibata, a researcher at Japan’s
National Institute of Advanced Industrial Science and
Technology, is a therapeutic pet-type robot, with the
appearance of a baby harp seal and about the size of a
newborn baby. It has tactile sensors and moves its tail
and flippers, and opens its eyes when petted. Artificial
intelligence software changes the robot’s behaviours
based on an array of sensors that monitor sound, light,
temperature and touch. It responds to sounds, can learn
its name and learns to respond to frequent words used
by its owner. It can show emotions such as surprise, hap-
piness, and anger, and will cry if it is not receiving suffi-
cient attention. It produces sounds similar to a real baby
seal and is active during the day and asleep at night.
Participants will be given the PARO and the research
assistant (RA) will repeat a short script: “This is PARO.
PARO is a companion animal. PARO can move. PARO
will respond when you touch and stroke PARO and to
your voice when you speak to PARO. Look at the reac-
tion of PARO’S eyes. I will leave you with PARO for a
short time for you to get to know PARO. I will sit over
there and read my book while you have PARO.”
Plush-Toy
Participants at sites allocated to the PT treatment group
will receive three individual non-facilitated sessions (with
PT) per week (Mon, Wed, Fri), for 15 min per session,
between the hours of 1300–1700, for a period of
10 weeks. The PT is a PARO that has had all robotic and
artificial intelligence capabilities disabled. Participants
will be given the PT and the RA will repeat a short
script: “This is X (PT name). X is a companion animal.
X cannot move. X can be touched and stroked and
spoken to. Look at X’s eyes. I will leave you with X for a
short time for you to get to know X. I will sit over there
and read my book while you have X.”
RAs receive at least 5 h of training specific to the inter-
vention. These trained RAs will deliver and introduce
the PARO or PT to participants at the start of each
session and collect the PARO or PT from participants at
the end of each session. In the session, residents will be
left alone to interact with PARO or PT, however, they
choose. As people with dementia often display agitated
behaviours during mid to late afternoon13 all sessions
will be conducted in the afternoon and in a naturalistic
environment (ie, wherever the participants are located
at the time of their allocated session, including
bedroom, dining area or communal area).
Three members of the team and the project manager
will assess adherence to the trial Intervention through
random examination of the video observations at
regular intervals throughout the trial.
Usual Care
Participants at sites allocated to the UC treatment group
will receive usual care.
A 10-week intervention will allow both short- (5 weeks)
and long-term follow-up (10 weeks). We will also
conduct a follow-up at 15 weeks, to examine long-term
sustainability following withdrawal of the intervention.
Outcomes
The trial has three primary outcomes of interest:
Agitation as measured by the Cohen-Mansfield Agitation
Inventory-Short Form (CMAI-SF; 14 short-item)14; mood
and engagement as measured by video observations via
a small GoPro Hero video camera at weeks 0 (baseline),
1, 5, 10 and 15 (follow-up). To ensure a distinct baseline,
the first video observation will be conducted in week 0
before the interventions or usual care commence.
Direct observations of participants for PARO and PT
treatment groups will occur 15 min before the interven-
tion and during the 15 min intervention (5 sessions
observed in total; total of 2.5 h per participant). The UC
(Control) group individuals will have the video observa-
tions undertaken for a 30 min period during 1300–1700
(5 sessions as per PARO and PT; total of 2.5 h per
participant).
Secondary outcome measures include: sleep duration,
step count measured by Sensewear (SW), change in psy-
chotrophic medication use, change in treatment costs
and staff and family perceptions of PARO/PT. The SW
armband will be placed on individual participants from
each group for a 24 h period at weeks 0 (baseline) and
15 (follow-up) as well as weeks 5 and 10 on a day when
the PARO or PT intervention is being delivered or, for
the UC group, during usual care (total of 72 h per par-
ticipant). To ensure a distinct baseline, the first SW
measurement will be conducted in week 0 before the
interventions or usual care commences. As needed
(PRN) psychotropic medication use will also be mea-
sured by a medication audit. Staff and family percep-
tions of PARO and PT will be assessed in semistructured
interviews within a fortnight of the completion of indi-
vidual interventions with a convenience sample of 20
family and 20 staff. Demographic information of families
and staff will be collected, including age, gender, ethni-
city, work category (for staff), relationship to person
with dementia, qualifications and employment (for
family).
Sample size
In line with outcomes observed in the pilot study and
similar outcomes in other research using an individua-
lised intervention for agitation reduction,15 16 a total
sample size of 345 participants, 115 in each group, will
be required to detect a 25% reduction in agitation level
(at a power of 0.90, α=0.05).16 The sample size was com-
puted using two steps. Sample size required for a simple
randomised complete trial design (RCT) was 75 in each
group. This was then multiplied by the design effect to
account for the nested structure in a C-RCT. Adjusting
to account for clustering based on an Intra Class
Correlation (ICC) of 0.07, we determined that at least
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115 patients would be required in each group if we were
to use 10 clusters per group (n=345). Allowing for a
potential drop out of 10%, increased the total targeted
sample to a recruitment sample of 380 participants. To
ensure this sample size, we will involve 35 sites in the
study with a target of 12 participants at each site.
Randomisation and allocation concealment
Facilities will be randomly assigned to the PARO, PT and
UC groups. Griffith University Centre for Health
Practice Innovation will administer the randomisation
process centrally via a secure web-based system.
Blinding
The Intervention Observer RAs will not be blinded to
intervention; hence they will not collect outcome data
and will be kept blind to all outcome measurements.
Intervention Data Collection RAs will be kept blind to
the intention of the study and to the alternative condi-
tions. RAs coding videos will be kept blind to the alter-
native treatment options, as they will each code one
treatment group. Family and participants will be kept
blind to the outcome measurements. Participants and
family will consent only to participation in the study as a
whole, not to participation in a particular treatment
group.
Data collection
The study data collected at each time point are sum-
marised in table 1.
Data management
To preserve confidentiality, all participants will be allo-
cated a unique study identifier, which will be used on all
data collection forms alongside participants’ initials. A
data manager for each treatment group will undertake
data entry. A separate password-protected database for
each treatment group will allow selected members of the
research team to link the participant and the study treat-
ment group. Access to the final data set will be available
only to the research team. Currently no plans for data
sharing have been arranged.
Analysis
Video data will be analysed using Noldus XT Pocket
Observer software. Agitated behaviour will be coded
according to the internationally validated instrument
CMAI-SF.14 A coding manual previously developed in
our pilot study11 will also be used for engagement and
mood states. Coders are assigned to coding video data
from one treatment group only. This will ensure that
coders are blinded to the other treatment alternatives.
Furthermore, coding of the preintervention videos
before coding of the intervention videos should elimin-
ate bias. Inter-rater reliability, the degree of concordance
between coders, will be set at a minimum of 0.90 and
0.85 for κ and ICC coefficients, respectively.17 This will
be assessed and established during training sessions,
after which the Noldus trainer will conduct random
checks of inter-rater reliability.
Descriptive statistics will be computed for participant
demographics and all outcomes measures. An
‘Intention-To-Treat’ (ITT) approach will be adopted in
which all LTC facilities are analysed according to the
treatment group into which they were randomised.
However, a per-protocol analysis will also be undertaken
as a sensitivity analysis. Where appropriate, multiple
imputation will be used to manage missing data.
Baseline variations between PARO, PT and UC groups
will be examined using χ² tests for categorical variables, t
tests for the normally distributed continuous variables
and Kruksal Wallis tests for continuous variables with
skewed distributions.
Cluster and individual level analyses will be carried
out to test all hypotheses. Generalised Linear Models
(GLM) for cluster level and Generalised Estimation
Equations (GEE) and/or Multi-Level Modeling (MLM)
for individual level data with adjustment for potential
covariates at both cluster and individual levels will be
used. As covariate data are proposed for collection at
both cluster (ie, LTC environmental data) and individual
(ie, participant’s demographic data, cognitive status and
risk of agitation) levels, the adjustment of these factors,
if significantly different at baseline between PARO, PT
and UC groups, will be carried out when using GEE or
MLM as appropriate, depending on the distributional
and other assumptions that may vary between the
outcome measures. The proposed a priori model-fitting
approach will identify (A) each outcome measure and
the covariates to be considered for inclusion in any mod-
elling approach; and (B) the potential confounding vari-
ables that are to be considered for inclusion in the
model with the intervention. STATA software program
will be used.
Cluster level analysis: Differences in primary outcome
measures (ie, agitation, mood and engagement)
between PARO, PT and UC groups, at both short-term
and long-term, will be reported. Secondary outcome
Table 1 Data collection
Baseline
Week
1
Week
5
Week
10
Week
15
Demographics X
RUDAS X
CMAI-SF X X X
Medication
Audit
X X X X
Sensewear
Measurements
X X X X
Video
observations
X X X X X
Interviews X
CMAI-SF, Cohen-Mansfield Agitation Inventory-Short Form;
RUDAS, Rowland Universal Dementia Assessment Scale.
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measures (ie, sleep duration, step count and PRN psy-
chotropic medication use) will also be compared
between PARO, PT and UC groups. Estimates will be
adjusted using GLM for any significant cluster level
covariates.
Individual level analysis of the outcome measures when
comparing between PARO, PT and UC groups will pri-
marily account for the intracluster correlation (ICC), to
increase the statistical power of the analysis. Analyses will
include statistical tests, GEE or MLM to account for the
clustering effect to avoid spuriously low p values, overly
narrow CIs and over-emphasising the impact of the
intervention.
A thematic analysis of the qualitative interviews will
explore family and staff perceptions of using PARO and
PT in LTC. No interim analyses are planned for this
trial.
Comparative cost analysis
A comparative cost analysis will be undertaken to esti-
mate the costs and cost offsets of the PARO and PT
intervention compared with UC. The analysis will take a
healthcare provider perspective. The duration of the
trial (15 weeks) will be used as the time horizon for the
within trial analysis; this will be extrapolated to
12 months. Twelve months is consistent with the war-
ranty period of use for PARO. Resource use including
the acquisition cost of PARO and additional staff and
monitoring costs will be measured during the C-RCT. A
weighted cost per day per patient of the intervention
will be calculated based on the expected life span of
PARO. Cost offsets due to reduction in use of psycho-
tropic medications will be calculated based on the
Dispensed Price per Maximum Quantity. Reduction in
adverse events such as falls and mortality expected by
the reduction in medication usage will be modeled from
previous research.18 19
TRIAL MANAGEMENT
Day-to-day running of the trial will be overseen by a
team, comprised of the Chief Investigators, Project
Manager, Cluster Leaders, and Statistican. Regular team
meetings will take place for the duration of the study.
The team will have responsibility for ensuring the com-
pliance and progress of the study in relation to regula-
tory, administrative, industry and safety issues.
Adverse event reporting
All adverse events will be recorded and reported to the
Human Research Ethics Committee, LTC administration
and families.
Ethics and dissemination
After randomisation of sites, potential participants and/
or proxies (if residents are unable to provide informed
consent) will be approached by the facility manager and
subsequently a project team member for written
informed consent to participate in a study exploring
robotic animals. They will be informed that participants
will receive one of three interventions and that consent
is to receive the intervention to which their facility has
been assigned and to undergo outcome measures. They
cannot consent to receive a particular type of interven-
tion. Where necessary, approval was also sought from
facility ethics committees.
Participants will have the right to withdraw from the
trial at any time for any reason, without giving a reason.
Participants or their representative who no longer wish
to participate in the trial may choose to either withdraw
completely, or to withdraw from the study intervention,
but continue to provide follow-up data. In such a situ-
ation, participants or their proxy will be asked if the
data collected up to the point of withdrawal may be
retained.
Dissemination
Findings will be presented at local and international
conference meetings and published in peer-reviewed
journals. A lay summary of the findings will be made
available to participants and representatives, and to each
facility. If PARO is shown to have an effect, the CIs will
develop guidelines to facilitate the use of PARO in LTC
facilities.
Trial status
The trial is currently in data collection. The first of the
facilities were recruited on 24th March 2014, facility ran-
domisation took place on 29 May 2014 and participant
recruitment started 14 June 2014.
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